VTE-BLEED Score

• Do not use this score as the sole basis for clinical decisions; consider the full clinical context, including comorbidities, concurrent medications, and patient preferences.
• This tool is not intended to definitively exclude patients from anticoagulation therapy. 
• Use results to support discussion of thrombotic versus bleeding risk.
• Tailor management to the individual patient and consult relevant guidelines for comprehensive care.

• Score ≥2 (elevated bleeding risk): 
  
  • Manage modifiable risk factors.
  • Use closer monitoring, especially during higher-risk periods (e.g., around procedures).
  • Consider adjustments to the anticoagulation approach, such as:
    
    • Careful medication selection (e.g., DOAC versus VKA).
    • Dose adjustment (e.g., prophylactic versus therapeutic dosing after a designated period).
    • Shorter anticoagulation duration (e.g., 3 months versus 6 months).
  • Evaluate the possibility of non-anticoagulant strategies.
  • Engage the patient in a discussion about risks and benefits.
• Score <2 (lower bleeding risk): Proceed with guideline-recommended anticoagulation, with routine follow-up and monitoring.

For detailed management, refer to guidelines from relevant medical societies (e.g., AHA/ACC/ACCP, ESC).

• Always assess for active or recent bleeding before starting or continuing anticoagulation. 
• For significant bleeding, discontinue or hold anticoagulation and evaluate for reversal or hemostatic intervention as appropriate. 
• Be alert to red-flag symptoms (e.g., hematemesis, melena, uncontrolled epistaxis) that may require immediate intervention, regardless of score. 
• Ensure that all patients on anticoagulation have appropriate access to follow-up care and monitoring.
• Do not use this tool in patients with severe renal impairment (creatinine clearance <30 mL/min).